Evaluating the efficacy of Rose Bengal-PVA combinations within PCL/PLA implants for sustained cancer treatment
Drug Delivery and Translational Research · 2025
DOI: 10.1007/s13346-024-01711-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Delivery and Translational Research, 2025. Verfasst von Sara Demartis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical, Physical, Mathematical and Natural Sciences, University of Sassari, Sassari, 07100, Italy. Hauptthemen laut MEDLINE: Polyesters, Polyvinyl Alcohol, Rose Bengal, Antineoplastic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Sassari.
Abstract (Originalsprache)
The current investigation aims to address the limitations of conventional cancer therapy by developing an advanced, long-term drug delivery system using biocompatible Rose Bengal (RB)-loaded polyvinyl alcohol (PVA) matrices incorporated into 3D printed polycaprolactone (PCL) and polylactic acid (PLA) implants. The anticancer drug RB’s high solubility and low lipophilicity require frequent and painful administration to the tumour site, limiting its clinical application. In this study, RB was encapsulated in a PVA (RB@PVA) matrix to overcome these challenges and achieve a localised and sustained drug release system within a biodegradable implant designed to be implanted near the tumour site. The RB@PVA matrix demonstrated an RB loading efficiency of 77.34 ± 1.53%, with complete RB release within 30 min. However, when integrated into implants, the system provided a sustained RB release of 75.84 ± 8.75% over 90 days. Cytotoxicity assays on PC-3 prostate cancer cells indicated an IC50 value of 1.19 µM for RB@PVA compared to 2.49 µM for free RB, effectively inhibiting cancer cell proliferation. This innovative drug delivery system, which incorporates a polymer matrix within an implantable device, represents a significant advancement in the sustained release of hydrosoluble drugs. It holds promise for reducing the frequency of drug administration, thereby improving patient compliance and translating experimental research into practical therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical, Physical, Mathematical and Natural Sciences, University of Sassari, Sassari, 07100, Italy.
- School of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, UK.
- School of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, UK. e.larraneta@qub.ac.uk.
- Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, 07100, Italy.
- Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, 07100, Italy. eligav@uniss.it.
ORCID-Profile: Elisabetta Gavini
Förderung
- Università degli Studi di Sassari
Zitieren
APA
Demartis, S., Picco, C. J., Larrañeta, E., Korelidou, A., Islam, R., Coulter, J. A., Giunchedi, P., Donnelly, R. F., Rassu, G., & Gavini, E. (2025). Evaluating the efficacy of Rose Bengal-PVA combinations within PCL/PLA implants for sustained cancer treatment. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-024-01711-w
Vancouver
Demartis S, Picco CJ, Larrañeta E, Korelidou A, Islam R, Coulter JA, et al. Evaluating the efficacy of Rose Bengal-PVA combinations within PCL/PLA implants for sustained cancer treatment. Drug Delivery and Translational Research. 2025. doi:10.1007/s13346-024-01711-w
BibTeX
@article{Demartis2025,
author = {Demartis, Sara and Picco, Camila J and Larrañeta, Eneko and Korelidou, Anna and Islam, Rayhanul and Coulter, Jonathan A and Giunchedi, Paolo and Donnelly, Ryan F and Rassu, Giovanna and Gavini, Elisabetta},
title = {Evaluating the efficacy of Rose Bengal-PVA combinations within PCL/PLA implants for sustained cancer treatment},
journal = {Drug Delivery and Translational Research},
year = {2025},
doi = {10.1007/s13346-024-01711-w}
}
EUVIMED